Latest news with #TULIP
Time of India
11-07-2025
- General
- Time of India
Indore shows the way to a beggar-free city at national workshop
Indore: Indore, which earned the 'beggar-free city' tag, showcased its plan and execution to senior officials from around 100 cities in a national-level workshop on Friday. The social justice department also assured support to empower marginalised artisans, who gave up begging and are now making 19 product items in Indore, by providing them with a platform for global exposure and sales of their products through e-marketing. The one-day workshop and training programme, focused on the 'Comprehensive Rehabilitation of Persons Engaged in Begging' under the SMILE sub-scheme, was chaired by Amit Yadav, Secretary of the Department of Social Justice and Empowerment. It saw participation from nodal officers and representatives of implementing agencies from across India. Rupali Jain, from an Indore-based NGO involved in the 'beggar-free city' campaign, informed the gathering about their plans and execution. This included extending care to persons with mental and other disabilities, bedridden and elderly individuals who were seeking alms to feed themselves, along with identifying and taking action against 'beggar-gangs'. Additionally, children rescued from begging were sent to schools, and homeless kids were provided shelters in different centres in Indore. Many rescued individuals are now making 19 products that were showcased in the workshop. Senior officials from the social justice department assured local officials of an online platform to sell these products through its 'TULIP' (Traditional Artisans' Upliftment Livelihood Programme). The goal of TULIP is to empower marginalised artisans by providing them with a platform for global exposure and sales of their products through e-marketing. In the workshop, Additional Secretary Karalin Khongwar Deshmukh delivered the welcome speech, followed by addresses from Principal Secretary Sonali Ponkshe Wayanganakar. Indore Collector Asheesh Singh, IMC Commissioner Shivam Verma, and ISCDL CEO Divyank Singh also marked their presence. The workshop featured sessions including that on 'Mobilisation/Relief and Initial Rehabilitation' and 'Self-employment and skill development'. In a panel discussion, representatives from Kerala, Uttarakhand, Uttar Pradesh, Bihar, and Rajasthan presented models implemented in their respective states. A presentation was also given on the revised guidelines of "SMILE-B", and feedback was collected from officials and NGO representatives.
Yahoo
05-06-2025
- Business
- Yahoo
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ('CVD') with elevated low-density lipoprotein cholesterol ('LDL-C'), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an R&D Day event for analysts and investors on June 11, 2025 beginning at 9:00 a.m. ET in New York City. Please join members of our management team, including: Michael Davidson, M.D., Chief Executive Officer, John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer, BJ Jones, Chief Commercial Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President. A live webcast of the R&D event will be available and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance. About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL CVOT in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company ContactMatthew PhilippeP: Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP: in to access your portfolio
Yahoo
05-06-2025
- Business
- Yahoo
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ('CVD') with elevated low-density lipoprotein cholesterol ('LDL-C'), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an R&D Day event for analysts and investors on June 11, 2025 beginning at 9:00 a.m. ET in New York City. Please join members of our management team, including: Michael Davidson, M.D., Chief Executive Officer, John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer, BJ Jones, Chief Commercial Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President. A live webcast of the R&D event will be available and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance. About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL CVOT in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company ContactMatthew PhilippeP: Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP:
Medscape
28-05-2025
- Health
- Medscape
Long-Term Anifrolumab Use Improves Quality of Life in Lupus
Patients with moderate to severe active systemic lupus erythematosus (SLE) who continued anifrolumab treatment over 4 years showed sustained improvements in health status and quality of life, along with improvements in health utilities and employment measures. METHODOLOGY: Researchers conducted an extension trial (TULIP-LTE) to assess the long-term effects of anifrolumab treatment on patient-reported outcomes in SLE at baseline through week 208. They included 369 patients with moderate to severe SLE who were randomly assigned to receive either 300 mg anifrolumab (n = 257; mean age, 43.4 years; 92% women) or placebo (n = 112; mean age, 41.4 years; 92% women) every 4 weeks. These patients had completed the 1-year TULIP-1 and TULIP-2 trials and maintained the same treatment in the long-term extension study. Exploratory endpoints were changes in patient-reported outcomes related to health status and health-related quality of life. TAKEAWAY: At week 208, the anifrolumab group had numerically higher Short Form-36 version 2 acute recall scores for mental health and bodily pain domains than the placebo group (least squares mean [LSM] difference, 3.7; 95% CI, −1.2 to 8.6 and 5.9; 95% CI, −0.7 to 12.5, respectively). The Short Form-6 Dimension scores showed numerically greater improvements in the anifrolumab group than in the placebo group, with differences evident from week 24 (LSM difference, 0.013; 95% CI, −0.007 to 0.032) and sustained through week 208 (LSM difference, 0.016; 95% CI, −0.010 to 0.042). Similarly, Patient Global Assessment and EuroQoL 5 Dimensions–derived Single Summary Utility Index scores showed numerically greater improvements in the anifrolumab group than in the placebo group at week 208. At week 208, the proportion of patients in paid employment remained stable in both the anifrolumab and placebo groups (45% vs 44%), with both groups showing similar reductions in the number of work hours missed in the preceding week. IN PRACTICE: 'These findings highlight the importance of including patient-reported outcomes as single, composite indices (eg, SF-6D) in clinical trials to allow comprehensive assessment of meaningful benefit for patients,' the authors wrote. SOURCE: This study was led by Vibeke Strand, MD, Division of Immunology and Rheumatology, Stanford University, Palo Alto, California, and was published online on May 2, 2025, in The Lancet Rheumatology . LIMITATIONS: The exploratory and post hoc nature of the analysis may have limited the interpretation of the results, as the trials were not powered for the exploratory endpoints examined. Patients with active, severe lupus nephritis or severe neuropsychiatric SLE were not included. Additionally, the study did not include any individuals with lived experience of SLE at any stage of its design, conduct, or reporting. DISCLOSURES: This study was funded by AstraZeneca. One author reported receiving honorarium and consulting fees from various pharmaceutical companies and other sources, including AstraZeneca. Another author reported receiving consulting fees from AstraZeneca. A few authors reported being current or former employees or holding stocks of AstraZeneca or having other ties with a biotechnology company.
